Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 6/20 | 0.33 |
| ▸ | F13A1 | P00488 | 5/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | TGM1 | P22735 | 4/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150887 | 0.88 | USP2 (0.34) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL21590670 | 0.88 | USP2 (0.32) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL21590903 | 0.80 | NR1H2 (0.35) | USP2SMN1; SMN2DDB1CRBNTGM2 | |
| SCHEMBL21590786 | 0.76 | USP2 (0.39) | USP2SMN1; SMN2DDB1CRBNTGM2 | |
| SCHEMBL2947368 | 0.74 | USP2 (0.41) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL21590750 | 0.73 | NR1H2 (0.36) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL21590782 | 0.72 | NR1H2 (0.34) | USP2SMN1; SMN2DDB1CRBNNR1H2 | |
| SCHEMBL22041872 | 0.70 | SMN1; SMN2 (0.36) | USP2SMN1; SMN2DDB1CRBNTGM2 | |
| SCHEMBL15475694 | 0.70 | USP2 (0.43) | USP2SMN1; SMN2DDB1CRBNTGM2 | |
| SCHEMBL27354187 | 0.70 | USP2 (0.38) | USP2SMN1; SMN2DDB1CRBNTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-112424196-A | Novel isoxazolyl ether derivatives as GABAA alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2019238633-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | USP2 3807/4885SMN1; SMN2 3404/4885DDB1 4710/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | USP2 3012/4885SMN1; SMN2 2455/4885DDB1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.